Everything below concerns triple agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
The first state to switch to this method was Ohio, on December 8, 2009. In 2011, after pressure from activist organizations, the manufacturers of pentobarbital and sodium thiopental halted the supply of the drugs to U.S. prisons performing lethal injections and required all resellers to do the same.
20 August – 2024 Ulster Unionist Party leadership election: Nominations open to elect the next leader of the Ulster Unionist Party. 21 August – 2024 Ulster Unionist Party leadership election: Doug Beattie rules himself out of running for re-election as UUP leader. 22–23 August – 2024 United Kingdom general election betting scandal: The Metropolitan Police ends its investigation into the betting scandal, saying that the offences being investigated have not met the "high bar" to prove misconduct in public office. The matter remains under investigation by the Gambling Commission. The UK government authorises the Infected Blood Compensation Authority to begin making payments to affected patients. 26 August – Keir Starmer cancels the appointment of Gwyn Jenkins as national security adviser. Questions are raised over Waheed Alli and his temporary pass to Number 10. 27 August – Keir Starmer delivers his first major speech a speech since becoming prime minister, and warns that the October budget will be "painful". The UK government cancels a £40m helicopter contract agreed by former prime minister Rishi Sunak. The UK government announces an extra £10.5m of funding to prepare for new EU border checks, with major ports receiving extra funding to prepare for the changes. The Scottish Fiscal Commission (SFC) warns the SNP government that “difficult decisions” are needed to balance its budget. 28 August – Starmer meets with German chancellor Olaf Scholz in Berlin to discuss UK–EU relations, before attending the Paralympics opening ceremony in Paris.
Large stockpiles of weapons-grade plutonium were built up by both the Soviet Union and the United States during the Cold War. The U.S. reactors at Hanford and the Savannah River Site in South Carolina produced 103 tonnes, and an estimated 170 tonnes of military-grade plutonium was produced in the USSR. Each year about 20 tonnes of the element is still produced as a by-product of the nuclear power industry. As much as 1000 tonnes of plutonium may be in storage with more than 200 tonnes of that either inside or extracted from nuclear weapons. SIPRI estimated the world plutonium stockpile in 2007 as about 500 tonnes, divided equally between weapon and civilian stocks. Radioactive contamination at the Rocky Flats Plant primarily resulted from two major plutonium fires in 1957 and 1969. Much lower concentrations of radioactive isotopes were released throughout the operational life of the plant from 1952 to 1992. Prevailing winds from the plant carried airborne contamination south and east, into populated areas northwest of Denver. The contamination of the Denver area by plutonium from the fires and other sources was not publicly reported until the 1970s. According to a 1972 study, co-authored by Edward Martell, "In the more densely populated areas of Denver, the Pu contamination level in surface soils is several times fallout", and the plutonium contamination "just east of the Rocky Flats plant ranges up to hundreds of times that from nuclear tests".
Extending the work of Vesalius into experiments on still living bodies (of both humans and animals), William Harvey and other natural philosophers investigated the roles of blood, veins and arteries. Harvey's De motu cordis in 1628 was the beginning of the end for Galenic theory, and alongside Santorio Santorio's studies of metabolism, it served as an influential model of quantitative approaches to physiology. In the early 17th century, the micro-world of biology was just beginning to open up. A few lensmakers and natural philosophers had been creating crude microscopes since the late 16th century, and Robert Hooke published the seminal Micrographia based on observations with his own compound microscope in 1665. But it was not until Antonie van Leeuwenhoek's dramatic improvements in lensmaking beginning in the 1670s—ultimately producing up to 200-fold magnification with a single lens—that scholars discovered spermatozoa, bacteria, infusoria and the sheer strangeness and diversity of microscopic life. Similar investigations by Jan Swammerdam led to a new interest in entomology and built the basic techniques of microscopic dissection and staining.
== External links == NASA Spinoff homepage NASA Spinoff back issues archive NASA spinoff database Home and City – relating everyday life to NASA research NASA Benefits to You NASA Office of the Chief Technologist NASA STI Program "The Economic Impacts of the U.S. Space Program" by Jerome Schnee, Rutgers University "A Sustainable Method for Quantifying the Benefits of NASA Technology Transfer"
Sources: en.wikipedia.org
For instance, less than half of those species found in Turkey are actually native. These have been referred to as neo-tulipae. Tulips are indigenous to mountainous areas with temperate climates, where they are a common element of steppe and winter-rain Mediterranean vegetation. They thrive in climates with long, cool springs and dry summers. Tulips are most commonly found in meadows, steppes and chaparral, but also introduced in fields, orchards, roadsides and abandoned gardens.
Heavy menstrual periods Endometriosis and chronic pelvic pain Adenomyosis and dysmenorrhea Anemia Endometrial hyperplasia (especially in pre-menopausal people who wish to maintain fertility in the treatment of endometrial hyperplasia) In some cases, use of a hormonal IUD may prevent a need for a hysterectomy. Advantages:
A swing check valve (or tilting disc check valve) is a check valve in which the disc, the movable part to block the flow, swings on a hinge or trunnion, either onto the seat to block reverse flow or off the seat to allow forward flow. The seat opening cross-section may be perpendicular to the centerline between the two ports or at an angle. Although swing check valves can come in various sizes, large check valves are often swing check valves. A common issue caused by swing check valves is known as water hammer. This can occur when the swing check closes and the flow abruptly stops, causing a surge of pressure resulting in high velocity shock waves that act against the piping and valves, placing large stress on the metals and vibrations in the system. Undetected, water hammer can rupture pumps, valves, and pipes within the system. The flapper valve in a flush-toilet mechanism is an example of this type of valve. Tank pressure holding it closed is overcome by manual lift of the flapper. It then remains open until the tank drains and the flapper falls due to gravity. Another variation of this mechanism is the clapper valve, used in applications such firefighting and fire life safety systems. A hinged gate only remains open in the inflowing direction. The clapper valve often also has a spring that keeps the gate shut when there is no forward pressure. Another example is the backwater valve (for sanitary drainage system) that protects against flooding caused by return flow of sewage waters.
== Career at Genentech == Because of the Kleiner and Perkins investment, Swanson and Boyer dissolved their partnership and created the legal entity Genentech. Kleiner and Perkins provided $100,000 on the May closing, and acquired 20,000 shares of preferred stock from Genentech. Swanson was made the president and treasurer of Genentech, and received a $2,500 per month salary, along with 25,000 shares. This marked the end of Swanson's unemployment, and the beginning of his career at Genentech. With funding secured, and the organizational structure formed, the first logical step forward was to begin experimenting with the procedure for the synthesis of insulin. Since Genentech lacked any laboratories of its own, the Boyer lab, as well as two other labs in the San Francisco area, were to be subcontracted to carry out the experiments. However, the scientists quickly realized that a step wise approach would be more practical; rather than immediately engineer a bacterium that synthesized insulin, they would engineer a bacterium that could synthesize somatostatin, a smaller hormone. Swanson resisted at first, since he believed that “If you are going to go for something, go for the real thing.” the "real thing" being insulin, in this case. He eventually agreed, albeit grudgingly. With a new research goal set up, Swanson proceeded to establish official research agreements with the institutions. He set up research agreements with the University of California and the City of Hope. Then, in early 1977, Swanson began a second round of funding, to jumpstart the somatostatin research.
Sources: en.wikipedia.org
=== Energy Harvesting and Storage === Flow batteries – synthesizing molecules for high-energy density electrolytes and highly-selective membranes in grid-scale energy storage systems Lithium-ion batteries – creating new molecules for use as electrode binders, electrolytes, electrolyte additives, or even for energy storage directly in order to improve energy density (using materials such as graphene, silicon nanorods, and lithium metal), power density, cycle life, and safety Solar cells – developing new materials for more efficient and cost-effective solar cells including organic, quantum dot or perovskite-based photovoltaics Photocatalytic water splitting – enhancing the production of hydrogen fuel using solar energy and advanced catalytic materials such as semiconductor nanoparticles
Also, cats, which are generally regarded as obligate carnivores, occasionally eat grass to regurgitate indigestible material (such as hairballs), aid with hemoglobin production, and as a laxative. Many mammals, in the absence of sufficient food requirements in an environment, suppress their metabolism and conserve energy in a process known as hibernation. In the period preceding hibernation, larger mammals, such as bears, become polyphagic to increase fat stores, whereas smaller mammals prefer to collect and stash food. The slowing of the metabolism is accompanied by a decreased heart and respiratory rate, as well as a drop in internal temperatures, which can be around ambient temperature in some cases. For example, the internal temperatures of hibernating Arctic ground squirrels can drop to −2.9 °C (26.8 °F); however, the head and neck always stay above 0 °C (32 °F). A few mammals in hot environments aestivate in times of drought or extreme heat, for example the fat-tailed dwarf lemur (Cheirogaleus medius).
Mitragynine pseudoindoxyl is a rearrangement product of 7-hydroxymitragynine, an active metabolite of mitragynine. Mitragynine pseudoindoxyl can be produced in the blood as a metabolite of 7-hydroxymitragynine.
Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals. The US Food and Drug Administration (FDA) approved it in July 2012.
== Concerns == Since microbes, namely Salmonella and Bacillus cereus, can persist in IMFs, other hurdles including reduction in pH and the use of preservatives is not unusual. However, additives such as nitrites and sulfites are associated with health concerns. Nitrites have a negative connotation in the food industry since they can combine with secondary amines to form nitrosamines, which are carcinogenic. Nitrites are linked to an increase risk in cancer and heart disease. Sulfite is another additive that is commonly avoided due to people having a sensitivity to sulfites. Yeast and mold are not fully inhibited by IMF processing because these microorganisms can tolerate water activity as low as 0.80. Browning can occur during storage of Intermediate moisture fruits and vegetables. Finally, sugar used commonly added as a humectant increases the caloric value of the food.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.